Catalyst Pharmaceuticals (CPRX) Shares Outstanding (Weighted Average) (2016 - 2026)
Catalyst Pharmaceuticals filings provide 17 years of Shares Outstanding (Weighted Average) readings, the most recent being $122.3 million for Q1 2026.
- On a quarterly basis, Shares Outstanding (Weighted Average) rose 0.64% to $122.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $122.3 million, a 0.64% increase, with the full-year FY2025 number at $122.3 million, up 3.24% from a year prior.
- Shares Outstanding (Weighted Average) hit $122.3 million in Q1 2026 for Catalyst Pharmaceuticals, roughly flat from $122.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $122.6 million in Q3 2025 to a low of $102.8 million in Q1 2022.
- Median Shares Outstanding (Weighted Average) over the past 5 years was $116.8 million (2024), compared with a mean of $112.9 million.
- Biggest five-year swings in Shares Outstanding (Weighted Average): dropped 0.99% in 2022 and later grew 11.6% in 2024.
- Catalyst Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $103.4 million in 2022, then increased by 2.81% to $106.3 million in 2023, then increased by 11.46% to $118.5 million in 2024, then grew by 3.24% to $122.3 million in 2025, then decreased by 0.03% to $122.3 million in 2026.
- The last three reported values for Shares Outstanding (Weighted Average) were $122.3 million (Q1 2026), $122.3 million (Q4 2025), and $122.6 million (Q3 2025) per Business Quant data.